| CUV Stock | | | EUR 0.84 0.02 2.33% |
CEO
Dr. Philippe J. Wolgen, MBA, M.D., is Chief Executive Officer, Managing Director, Executive Director of Clinuvel Pharmaceuticals Ltd. Dr Wolgen was appointed as Managing Director of CLINUVEL in November 2005 to lead the corporate turnaround of the Group. Under his leadership a longterm strategy for CLINUVEL was devised and the lead product SCENESSE reformulated, its medical application identified, and European marketing authorisation ultimately obtained. SCENESSE is the first melanocortin drug to have completed a clinical trial program and obtain marketing authorisation in a major market. Dr Wolgen was instrumental in rebuilding a share register of longterm sophisticated and institutional investors. His international contacts and network contribute to the strategic support CLINUVEL enjoys globally. He led CLINUVEL to attract more than AUD95 million in direct funding to develop and launch SCENESSE and succeeded in guiding the Group through a complex pharmaceutical development program. Dr Wolgen is now leading the Groups expansion, with an immediate focus on the US and the further development of the Groups product pipeline in various market segments. His focus was to establish a professional management team to execute the corporate objectives set and to prepare the next generation of managers. Dr Wolgens long track record shows a strongly focussed, competitive and ethical professional who perseveres in meeting business objectives. He holds an MBA from Columbia University NY and the London Business School. Trained as a craniofacial surgeon, Dr Wolgen obtained his MD from the University of Utrecht, the Netherlands. since 2005.
| Tenure | 19 years |
| Professional Marks | MBA |
| Phone | 852 3959 2888 |
| Web | https://www.realord.com.hk |
Wolgen holds an MBA from Columbia University NY and the London Business School. Trained as a surgeon Dr. Wolgen holds an MD from the Universiteit Utrecht, the Netherlands. He is Nonvoting member of the Audit and Risk committee and the Remuneration and Nomination committee.
Realord Group Management Efficiency
Realord Group's management efficiency ratios could be used to measure how well Realord Group manages its routine affairs as well as how well it operates its assets and liabilities.
Realord Group Holdings has accumulated 11.1
B in total debt with debt to equity ratio
(D/E) of 2.31, implying the company greatly
relies on financing operations through barrowing. Realord Group Holdings has a current ratio of 1.18, suggesting that it
is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Realord Group until it has trouble settling it off, either with new capital or with free cash flow. So, Realord Group's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Realord Group Holdings sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Realord to invest in growth at high rates of return. When we think about Realord Group's use of debt, we should always consider it together with cash and equity.
Similar Executives
Realord Group Holdings Limited, an investment holding company, engages in the commercial printing, hangtag, motor vehicles parts, financial service, trading, property, and environmental protection businesses in the Peoples Republic of China, Hong Kong, Japan, and internationally. Realord Group Holdings Limited is a subsidiary of Manureen Holdings Limited. REALORD GRP operates under Waste Management classification in Germany and is traded on Frankfurt Stock Exchange. It employs 513 people. Realord Group Holdings (CUV) is traded on Frankfurt Exchange in Germany and employs 513 people.
Management Performance
Realord Group Holdings Leadership Team
Elected by the shareholders, the Realord Group's board of directors comprises two types of representatives: Realord Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Realord. The board's role is to monitor Realord Group's management team and ensure that shareholders' interests are well served. Realord Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Realord Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan Smith, Non-Executive Director | |
| Madam Su, CEO Director | |
| Xiaodong Lin, Ex Director | |
| Willem Blijdorp, Non-Executive Chairman of the Board | |
| Jeffrey Rosenfeld, Non-Executive Director | |
| Philippe Wolgen, Chief Executive Officer, Managing Director, Executive Director | |
| Karen Agersborg, Non-Executive Director | |
| Chin Tsang, CFO Sec | |
| Darren Keamy, Chief Financial Officer, Company Secretary | |
| Xiaohui Lin, Ex Chairman | |
| Dennis Wright, Vice President - Scientific Affairs | |
| Brenda Shanahan, Non-Executive Independent Director | |
Realord Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Realord Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Realord Stock
Realord Group financial ratios help investors to determine whether Realord Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Realord with respect to the benefits of owning Realord Group security.